CSPC Pharmaceutical Group (HK:1093) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CSPC Pharmaceutical Group Limited has announced that its new drug, Omalizumab for Injection (branded as Enyitan®), has received marketing approval from the National Medical Products Administration (NMPA) of China. Enyitan® represents the first biosimilar of Xolair® in China, intended for patients over 12 years old with chronic spontaneous urticaria unresponsive to H1 antihistamine treatments. This approval marks a significant expansion of CSPC’s product line in the autoimmune disease category.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.